A freshly-amended 13D filing with the US SEC showed that Sam Isaly’s OrbiMed Advisors has sold some of its shares of Affimed N.V. (NASDAQ:AFMD), hence its stake in the company currently consists of 3.38 million common shares (which include 326,650 shares that can be obtained upon the Carve-Out Agreement), representing 10.15% of the float. Previously, the fund’s stake stood at 3.78 million shares, according to its 13F filing for the end of June.
Affimed N.V. is a clinical-stage biopharmaceutical company that works on producing cancer immunotherapies. Since the beginning of the year, the company’s stock has lost 60.39%. For the second quarter of 2016, Affimed N.V. disclosed a loss per share of €0.24 ($0.27) missing the estimates of a loss per share of €0.20, and revenue of €2.1 million, topping the estimates of €1.9 million.
Among investors from our database, nine reported long positions in Affimed N.V. (NASDAQ:AFMD) at the end of June, up by one from the previous quarter. Some of the bullish investors include Bain Capital’s Brookside Capital with a position valued at $5.20 million, James A. Silverman’s Opaleye Management which held a position worth around $1.48 million, Louis Bacon’s Moore Capital Management, and Julian and Felix Baker’s Baker Bros. Advisors.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| OrbiMed Advisors | 0 | 3,375,000 | 0 | 3,375,000 | 3,375,000 | 10.15% |
| OrbiMed Capital GP III | 0 | 3,343,965 | 0 | 3,343,965 | 3,343,965 | 10.05% |
| Samuel D. Isaly | 0 | 3,375,000 | 0 | 3,375,000 | 3,375,000 | 10.15% |
Page 1 of 12 – SEC Filing
AFFIMED N.V.
COMMON STOCK
N01045108
Telephone: (212) 739-6400
September 22, 2016
(Date of Event Which Requires Filing of this Statement)
